Novartis Ag Adr Stock Price To Sales
| NVS Stock | USD 104.87 1.06 1.02% |
Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 4.52 | 3.86 |
Novartis | Price To Sales |
Novartis AG ADR Company Price To Sales Analysis
Novartis' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Novartis Price To Sales | 4.20 X |
Most of Novartis' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novartis Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Novartis is extremely important. It helps to project a fair market value of Novartis Stock properly, considering its historical fundamentals such as Price To Sales. Since Novartis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novartis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novartis' interrelated accounts and indicators.
Click cells to compare fundamentals
Novartis Price To Sales Historical Pattern
Today, most investors in Novartis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novartis' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novartis price to sales as a starting point in their analysis.
Novartis Price To Sales |
| Timeline |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Novartis Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Novartis AG ADR has a Price To Sales of 4.1983 times. This is 80.38% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to sales for all United States stocks is 63.24% higher than that of the company.
Novartis Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in price to sales category among its peers.
Novartis ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novartis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novartis' managers, analysts, and investors.Environmental | Governance | Social |
Novartis Fundamentals
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 227.34 B | ||||
| Shares Outstanding | 2 B | ||||
| Shares Owned By Institutions | 6.74 % | ||||
| Number Of Shares Shorted | 4.79 M | ||||
| Price To Earning | 9.22 X | ||||
| Price To Book | 4.84 X | ||||
| Price To Sales | 4.20 X | ||||
| Revenue | 46.66 B | ||||
| Gross Profit | 36.74 B | ||||
| EBITDA | 18.29 B | ||||
| Net Income | 8.57 B | ||||
| Cash And Equivalents | 4.64 B | ||||
| Cash Per Share | 8.84 X | ||||
| Total Debt | 26.35 B | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 21.67 X | ||||
| Cash Flow From Operations | 14.46 B | ||||
| Short Ratio | 3.83 X | ||||
| Earnings Per Share | 5.73 X | ||||
| Price To Earnings To Growth | 3.12 X | ||||
| Target Price | 116.16 | ||||
| Number Of Employees | 76.06 K | ||||
| Beta | 0.51 | ||||
| Market Capitalization | 209.66 B | ||||
| Total Asset | 99.94 B | ||||
| Retained Earnings | 49.65 B | ||||
| Working Capital | 4.09 B | ||||
| Current Asset | 22.84 B | ||||
| Current Liabilities | 23.71 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 3.53 % | ||||
| Net Asset | 99.94 B | ||||
| Last Dividend Paid | 3.92 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.